PLx Pharma (NASDAQ: PLXP) is one of 287 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its rivals? We will compare PLx Pharma to related companies based on the strength of its earnings, institutional ownership, profitability, dividends, valuation, risk and analyst recommendations.
Institutional and Insider Ownership
21.9% of PLx Pharma shares are owned by institutional investors. Comparatively, 49.7% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 47.7% of PLx Pharma shares are owned by company insiders. Comparatively, 17.5% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares PLx Pharma and its rivals revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|PLx Pharma||N/A||-$21.32 million||-1.39|
|PLx Pharma Competitors||$290.27 million||$35.99 million||58.47|
PLx Pharma’s rivals have higher revenue and earnings than PLx Pharma. PLx Pharma is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
This is a summary of current ratings and target prices for PLx Pharma and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|PLx Pharma Competitors||925||3348||11856||237||2.70|
As a group, “Bio Therapeutic Drugs” companies have a potential upside of 41.19%. Given PLx Pharma’s rivals higher probable upside, analysts plainly believe PLx Pharma has less favorable growth aspects than its rivals.
This table compares PLx Pharma and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|PLx Pharma Competitors||-5,441.68%||-162.70%||-35.92%|
Risk and Volatility
PLx Pharma has a beta of 1.82, indicating that its stock price is 82% more volatile than the S&P 500. Comparatively, PLx Pharma’s rivals have a beta of 2.40, indicating that their average stock price is 140% more volatile than the S&P 500.
PLx Pharma rivals beat PLx Pharma on 8 of the 13 factors compared.
About PLx Pharma
PLx Pharma Inc., formerly Dipexium Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is a late stage specialty pharmaceutical company focusing on commercializing its lead products: Aspertec 325 mg and Aspertec 81 mg (Aspertec). The Company’s products and technology includes PLxGuard delivery system, Aspertec 325 mg, PL1100/PL1200 Ibuprofen. PLxGuard delivery system uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs to selectively release these drugs to targeted portions of the GI tract. The Company’s lead product Aspertec 325 mg is a liquid-fill aspirin capsule for prevention of cardiovascular disease. Through PLxGuard delivery system the Company creates a lipid-based formulation of ibuprofen, PL1200 Ibuprofen Capsules, 200 mg.
Receive News & Ratings for PLx Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PLx Pharma and related companies with MarketBeat.com's FREE daily email newsletter.